公开(公告)号：US20190276852A1

公开(公告)日：2019-09-12

申请号：US16348549

申请日：2017-11-14

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Yong-Soo CHOI ,  Chang-koo YUN ,  Min-Jin KIM ,  Jung Uk HWANG ,  Chun-Hyung KIM ,  Youngjun LEE

IPC分类号： C12N15/87 ,  C12N5/0775 ,  C12N5/0789 ,  C12N5/071 ,  C12N5/095 ,  C12N5/0783 ,  C12N5/078 ,  C12N5/077 ,  C12N5/0793 ,  G01N33/50

摘要： The present invention relates to a method for delivering exogenous mitochondria into cells and, more specifically, to a method for efficiently delivering, into the cytoplasm of target cells to be injected, mitochondria isolated from donor cells.

公开(公告)号：US20220211762A1

公开(公告)日：2022-07-07

申请号：US17607389

申请日：2020-04-27

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem HAN ,  Chun-Hyung KIM ,  Shin-Hye YU ,  Seo-Eun LEE ,  Sang-Min LIM ,  Hahnsun JUNG ,  Kwangmin NA ,  Yoon Mi HAN ,  Jun Young SON ,  Jong-Cheon HA ,  Kyunghee JUNG ,  Young-Cheol KANG ,  Eun-Seo LEE ,  Mi Jin KIM ,  Yong-Soo CHOI ,  Jung Uk HWANG ,  Min Ji LEE ,  Kyuseok KIM ,  Tae Nyoung CHUNG

IPC分类号： A61K35/19 ,  A61K35/28 ,  A61K45/06 ,  A61P31/00

摘要： The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

公开(公告)号：US20210052659A1

公开(公告)日：2021-02-25

申请号：US16964476

申请日：2019-02-07

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Yong-Soo CHOI ,  Jung Uk HWANG ,  Kyuboem HAN ,  Chun-Hyung KIM

IPC分类号： A61K35/28 ,  A61K35/34 ,  A61K35/52

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

公开(公告)号：US20200009198A1

公开(公告)日：2020-01-09

申请号：US16464928

申请日：2017-11-28

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Yong-Soo CHOI ,  Chang-koo YUN ,  Mi-Jin KIM ,  Jung Uk HWANG

IPC分类号： A61K35/50 ,  A61P9/10

摘要： The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.